National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) for classical Hodgkin Lymphoma

Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

Rapid Review

Commenced Completed Outcome
22/11/2016 18/01/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The HSE has approved reimbursement following confidential price negotiations October 2017.